Premium
Anti‐SGPG antibody in CIDP: Nosological position of IgM anti‐MAG/SGPG antibody‐associated neuropathy
Author(s) -
Tagawa Yumi,
Yuki Nobuhiro,
Hirata Koichi
Publication year - 2000
Publication title -
muscle and nerve
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.025
H-Index - 145
eISSN - 1097-4598
pISSN - 0148-639X
DOI - 10.1002/(sici)1097-4598(200006)23:6<895::aid-mus8>3.0.co;2-g
Subject(s) - medicine , antibody , chronic inflammatory demyelinating polyneuropathy , gammopathy , immunoglobulin m , polyneuropathy , immunoelectrophoresis , immunology , macroglobulinemia , monoclonal , monoclonal antibody , pathology , immunoglobulin g , multiple myeloma
Polyneuropathy with monoclonal gammopathy usually is considered a nosological entity different from chronic inflammatory demyelinating polyneuropathy (CIDP). Criteria proposed by the American Academy of Neurology AIDS Task Force (1991), however, show monoclonal gammopathy to be a condition concurrent with CIDP. The purpose of this study was to clarify the nosological relationship between CIDP and IgM anti‐myelin‐associated glycoprotein (MAG)/sulfated glucuronyl paragloboside (SGPG)‐associated polyneuropathy. We investigated IgM anti‐MAG/SGPG antibody in 85 CIDP patients by various methods, then examined the relation of M‐protein to the presence of IgM anti‐MAG/SGPG antibody. In our large study, 17 (20%) of 85 CIDP patients had high IgM anti‐SGPG antibody titers in the enzyme‐linked immunosorbent assay. This was confirmed by thin‐layer chromatography‐immunostaining for IgM anti‐SGPG antibody and immunoblotting for IgM anti‐MAG antibody. Immunoelectrophoresis and immunofixation, respectively, detected IgM M‐protein in 6 (35%) and 13 (76%) of the 17 CIDP patients. We conclude that some patients with IgM anti‐MAG/SGPG antibody with or without monoclonal gammopathy may be diagnosed as having CIDP, when patients are diagnosed according to the current CIDP criteria. © 2000 John Wiley & Sons, Inc. Muscle Nerve 23: 895–899, 2000